Neurocrine to buy Soleno Therapeutics for 2.9 billion
Neurocrine Biosciences will acquire rare disease drugmaker Soleno Therapeutics for 2.9 billion dollars in cash. The companies announced the deal on Monday.
Xurve View
Insights:
Xurve View
NEUROCRINE BIOSCIENCES INC has reached a definitive agreement to acquire SOLENO THERAPEUTICS INC for approximately $2.9 billion in cash. The announcement, made on Monday, signifies a strategic expansion for the biopharmaceutical firm as it seeks to bolster its portfolio within the rare disease sector.
